Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reifenberger

Showing results (521-530 of 562) with videos related to

Pageof 57
Sort By:
Acta Neuropathologica|July 7, 2018
FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytomaPhilipp Sievers, Damian Stichel, Daniel Schrimpf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2022
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaSied Kebir, Vivien Ullrich, Pia Berger, et al.
Nature Medicine|June 25, 2013
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1Martje Tönjes, Sebastian Barbus, Yoon Jung Park, et al.
Cell Death & Disease|September 29, 2021
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastomaUlvi Ahmadov, Daniel Picard, Jasmin Bartl, et al.
Brain Pathology (Zurich, Switzerland)|April 21, 2020
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and gradingDavid N Louis, Pieter Wesseling, Kenneth Aldape, et al.
Neuropathology and Applied Neurobiology|August 17, 2022
Anaplastic ganglioglioma-A diagnosis comprising several distinct tumour typesAnnekathrin Reinhardt, Kristin Pfister, Daniel Schrimpf, et al.
Journal for Immunotherapy of Cancer|January 13, 2023
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammationViktoria Marquardt, Johanna Theruvath, David Pauck, et al.
Acta Neuropathologica|December 15, 2020
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1Philipp Sievers, Martin Sill, Christina Blume, et al.
Neuro-Oncology|January 22, 2025
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutantEmilie Le Rhun, Andrea Bink, Joerg Felsberg, et al.
Acta Neuropathologica Communications|January 11, 2022
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survivalAzadeh Ebrahimi, Andrey Korshunov, Guido Reifenberger, et al.
Pageof 57

Showing results (521-530 of 562) with videos related to

Sort By:
Pageof 57
Acta Neuropathologica|July 7, 2018
FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytomaPhilipp Sievers, Damian Stichel, Daniel Schrimpf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2022
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaSied Kebir, Vivien Ullrich, Pia Berger, et al.
Nature Medicine|June 25, 2013
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1Martje Tönjes, Sebastian Barbus, Yoon Jung Park, et al.
Cell Death & Disease|September 29, 2021
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastomaUlvi Ahmadov, Daniel Picard, Jasmin Bartl, et al.
Brain Pathology (Zurich, Switzerland)|April 21, 2020
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and gradingDavid N Louis, Pieter Wesseling, Kenneth Aldape, et al.
Neuropathology and Applied Neurobiology|August 17, 2022
Anaplastic ganglioglioma-A diagnosis comprising several distinct tumour typesAnnekathrin Reinhardt, Kristin Pfister, Daniel Schrimpf, et al.
Journal for Immunotherapy of Cancer|January 13, 2023
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammationViktoria Marquardt, Johanna Theruvath, David Pauck, et al.
Acta Neuropathologica|December 15, 2020
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1Philipp Sievers, Martin Sill, Christina Blume, et al.
Neuro-Oncology|January 22, 2025
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutantEmilie Le Rhun, Andrea Bink, Joerg Felsberg, et al.
Acta Neuropathologica Communications|January 11, 2022
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survivalAzadeh Ebrahimi, Andrey Korshunov, Guido Reifenberger, et al.
Pageof 57